Fintel reports that on June 28, 2024, Guggenheim upgraded their outlook for Guardant Health (NasdaqGS:GH) from Neutral to Buy.
Analyst Price Forecast Suggests 27.74% Upside
As of June 12, 2024, the average one-year price target for Guardant Health is 36.89. The forecasts range from a low of 28.28 to a high of $49.35. The average price target represents an increase of 27.74% from its latest reported closing price of 28.88.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Guardant Health is 757MM, an increase of 25.43%. The projected annual non-GAAP EPS is -4.47.
What is the Fund Sentiment?
There are 529 funds or institutions reporting positions in Guardant Health. This is an decrease of 67 owner(s) or 11.24% in the last quarter. Average portfolio weight of all funds dedicated to GH is 0.15%, an increase of 3.97%. Total shares owned by institutions decreased in the last three months by 2.55% to 128,863K shares. 
The put/call ratio of GH is 1.42, indicating a bearish outlook.
What are Other Shareholders Doing?
Baillie Gifford holds 6,232K shares representing 5.09% ownership of the company. In its prior filing, the firm reported owning 6,179K shares , representing an increase of 0.86%. The firm decreased its portfolio allocation in GH by 71.38% over the last quarter.
Deep Track Capital holds 6,000K shares representing 4.90% ownership of the company. In its prior filing, the firm reported owning 5,000K shares , representing an increase of 16.67%. The firm decreased its portfolio allocation in GH by 21.50% over the last quarter.
Cadian Capital Management holds 5,793K shares representing 4.73% ownership of the company. In its prior filing, the firm reported owning 710K shares , representing an increase of 87.74%. The firm increased its portfolio allocation in GH by 455.39% over the last quarter.
Eventide Asset Management holds 4,179K shares representing 3.42% ownership of the company. In its prior filing, the firm reported owning 3,888K shares , representing an increase of 6.97%. The firm decreased its portfolio allocation in GH by 21.24% over the last quarter.
Temasek Holdings holds 4,111K shares representing 3.36% ownership of the company. In its prior filing, the firm reported owning 3,673K shares , representing an increase of 10.65%. The firm decreased its portfolio allocation in GH by 15.57% over the last quarter.
Guardant Health Background Information
(This description is provided by the company.)
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. These tests fuel development of its LUNAR screening program, which aims to address the needs of asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
